Lawmakers have proposed the PASTEUR Act to address what health experts describe as a growing global antimicrobial resistance crisis that threatens public health preparedness.

The legislation would establish a subscription-style payment model between the federal government and pharmaceutical companies that successfully develop novel antimicrobial drugs. Under this framework, companies would receive guaranteed payments in exchange for ensuring access to new antibiotics and other antimicrobial treatments.

The proposed system aims to solve a long-standing market failure in antimicrobial drug development, where traditional sales models have proven inadequate to incentivize sufficient research and development. Many pharmaceutical companies have reduced investment in antibiotic research due to limited commercial returns, as these drugs are typically used sparingly and for short durations.

Proponents argue the subscription model would provide financial assurance to developers while guaranteeing government access to critical medications during health emergencies. The approach mirrors successful public-private partnerships used in other sectors where market incentives alone have proven insufficient.

Antimicrobial resistance occurs when bacteria, viruses, and other pathogens evolve to survive treatments that once effectively eliminated them. Health officials warn that without new drug development, routine medical procedures could become increasingly dangerous as existing treatments lose effectiveness.